Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: BJU Int. 2012 Apr 3;110(9):1332–1337. doi: 10.1111/j.1464-410X.2012.10998.x

TABLE 2.

Median symptom score for all treatment groups a different time points relative to enrolment, treatment and last follow-up

Baseline to last assessment before
treatment
Last assessment before treatment to
first assessment after treatment
First assessment after treatment to
last assessment

Baseline
Median
(Q1, Q3)
Last
Median
(Q1, Q3)
P Last
Median
(Q1, Q3)
First
Median
(Q1, Q3)
P First
Median
(Q1, Q3)
Last
Median
(Q1, Q3)
P
None* 4 (2, 7) 6 (2, 10) <0.001 - - - - - -
α-AR 7 (4, 10) 11 (6, 15) <0.001 11 (7, 15) 12 (6, 17) 0.16 11 (6, 16) 13 (8, 17) < 0.001
5-ARI 7 (3, 12) 12 (7, 17) <0.001 10 (6, 16) 10 (6, 15) 0.35 10 (6, 15) 11 (6, 17) 0.03
Vaporization 11 (5, 17) 18 (14, 22) <0.001 15 (13, 20) 9 (6, 11) 0.001 10 (8, 12) 15 (8, 20) 0.84
TURP 9 (4, 14) 15 (10, 19) <0.001 16 (11, 19) 6 (2, 10) <0.0001 7 (2, 12) 8 (3, 13) 0.07

α-ARs, α-adrenergic receptor inhibitors; 5-ARI, 5α-reductase inhibitors; TURP, transurethral resection of the prostate.

*

Median symptom score from baseline to last follow-up assessment.

t test P value.